The lung cancer has high mortality worldwide due to the lack of symptoms and often late diagnosis (> 70% patients present at an advanced stage). The current early diagnosis of lung cancer is often via chest X-ray or low-dose computed tomography, which can be expensive and harmful for periodical test and sometimes fail to achieve early diagnosis. Therefore, there is an urgent need to develop a cost-effective and convenient technology for close investigation of high risk groups such as smokers.
Exosomes are extracellular vesicles secreted by cells. Exosomes excreted from normal and cancer cells are substantially different and cancer derived exosomes can be detected at very early stage of cancer. Thus, our solution is to employ exosomes for lung cancer early diagnosis.
In 2020, the global lung cancer screening market size was $2.61 billion and the market is continually growing at the rate of 8.1% due to the rising incidence of lung cancer caused by obesity, smoking and pollution. And the global whole cancer diagnostic market will reach $268.1 billion by 2028.Our clients will be the hospital and high risks of groups who need regular and convenient examination. Our first product will be based on lung cancer diagnosis and then expand to multi-cancer detection.